

Fig. S1. HSP2 effectively suppresses the growth, oxygen consumption rates, and ATP generation in subcutaneous A549-luc NSCLC tumor xenografts. (A) Sizes of H1299 tumors (mm3)from mice treated with HSP2 for 1.5 weeks (mid-point) or treated with HSP2/CycT for 3 weeks (end-point). (B) Photos showing excised tumors from NOD SCID mice treated with saline (control) or HSP2 (25 mg/kg I.V every 3 days) for 3 weeks (n=4/group). (B) Average weights for control and treated tumors shown in A. (C) Average body weights of control and treated mice bearing tumors shown in A. (D) Oxygen consumption rates (OCRs) measured in cells from control and treated tumors. (E) ATP levels measured in cells from control and treated tumors. Data are plotted as mean ± SEM. For statistical analysis, the levels in treated tumors were compared to the levels in control tumors with a Welch 2-sample t-test. \*, P < 0.05.